Aimovig blocks the calcitonin gene-related peptide receptor (CGRP-R), which is considered to play an important role in migraine. The drug’s effectiveness for the preventive treatment of migraine was
The regulator issued a complete response letter to Evolus citing deficiencies related to chemistry, manufacturing and controls processes. Evolus noted that the FDA did not identify any deficiencies
The series B financing round was headed by Sequoia China and LYFE Capital, and supported by existing series A investors such as VI Ventures and Nest.Bio Ventures and
Retacrit has been indicated for the treatment of anemia resulting from chronic kidney disease, chemotherapy, or use of zidovudine in HIV-infected patients. The FDA has also approved Retacrit for treating anemia
AurKa Pharma was established as part of the TVM Life Science Ventures VII fund, to develop an Aurora kinase A inhibitor called AK-01. The oncology compound was discovered originally
The study has failed to achieve statistically-significant reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca is continuing the Terranova trial, which is also a
In 2010, the oral disease-modifying therapy (DMT) was approved by the US Food and Drug Administration (FDA) for the treatment of RMS for patients aged 18 years and
Armo is currently developing drugs that are designed to trigger the immune system of cancer patients to identify and kill tumors. With the acquisition, Lilly expects to strengthen
The specialty pharmaceutical company had submitted a new drug application, seeking approval for Tlando as TRT for adult males with conditions caused by deficiency of endogenous testosterone (hypogonadism). Lipocine
The approval has been granted for Lynparza (olaparib) tablets (300mg twice daily) to be used as a maintenance therapy for patients with platinum-sensitive relapsed high-grade, epithelial ovarian, fallopian
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.